Key Points

  • 1. Moderna's stock price has surged over 10% and reached its highest level since January, indicating a notable rebound after a lackluster performance in 2023.
  • 2. The biotech firm is starting a mid-stage clinical trial for its experimental cancer vaccine in collaboration with Merck, focusing on patients with cutaneous squamous cell carcinoma.
  • 3. UBS analysts believe that Moderna's Phase 3 cytomegalovirus (CMV) data, expected later this year, could serve as a significant upside driver for the stock and present a substantial opportunity estimated at over $3 billion.
  • 4. Merck has initiated a new Phase 3 study involving Moderna's cancer vaccine V940, demonstrating continued confidence and substantial investment in the program.
  • 5. Moderna anticipates the initial regulatory approvals of its respiratory syncytial virus (RSV) vaccine in the first half of 2024 and expects research and development expenses for the full year 2024 to be approximately $4.5 billion.

Moderna (NASDAQ: MRNA) is witnessing a significant surge in its stock price on Monday, with shares soaring more than 10% and surpassing the $114 per share milestone. This upswing has propelled MRNA to its highest level since January, marking a notable rebound after a lackluster performance in 2023.

So, what's behind Moderna's stock rally?

According to information from a government trial website, the biotech firm is commencing a mid-stage clinical trial to evaluate its experimental cancer vaccine in patients diagnosed with cutaneous squamous cell carcinoma, a type of skin cancer. This trial is being conducted in collaboration with Merck, a pharmaceutical giant.

Additionally, analysts at UBS released a note to clients on Monday, highlighting Moderna's latent virus platform during a fireside chat. They emphasized the potential significance of the Phase 3 cytomegalovirus (CMV) data expected later this year, which they view as an underrated catalyst for Moderna's shares and a substantial opportunity estimated at over $3 billion for the company.

"We believe Moderna's platform and broader pipeline are undervalued, and we are particularly focused on the potential impact of Phase 3 CMV data, which could serve as a significant upside driver for the stock," stated UBS analysts.

Meanwhile, Jefferies, maintaining a Buy rating and $115 price target on Moderna, pointed out that Merck has initiated a new Phase 3 study involving Moderna's cancer vaccine V940. This marks the third Phase 3 trial for Merck, indicating continued confidence and substantial investment in the program.

Recent Updates from Moderna:

In its fourth-quarter earnings report, Moderna acknowledged 2023 as a transitional year as it adjusted to the evolving market dynamics. Despite the challenges, the company highlighted significant progress across various therapeutic areas, including infectious diseases, oncology, and rare diseases. Moreover, Moderna noted a rise in its market share in the U.S. for COVID-19-related products.

Looking ahead, Moderna anticipates the initial regulatory approvals of its respiratory syncytial virus (RSV) vaccine (mRNA-1345) to commence in the first half of 2024. The company also expects research and development expenses for the full year 2024 to be approximately $4.5 billion.

Furthermore, Moderna provided a comprehensive pipeline update earlier this year, revealing that it entered 2024 with 45 therapeutic and vaccine programs, with nine in late-stage development. The company foresees profitability for its COVID-19 franchise in 2024 and beyond, projecting approximately $4 billion in product sales for 2024, primarily driven by COVID-19 vaccine sales and the launch of its RSV vaccine.

In January, Moderna announced the full enrollment of the Phase 3 trial for its combination vaccine targeting seasonal flu and COVID-19, with data expected later in 2024. This development underscores Moderna's commitment to advancing innovative solutions to address pressing public health challenges.


Related Articles

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $39.7B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA